FDA grants priority review to Roche’s Tecentriq monotherapy as first-line treatment of certain people with advanced non-small cell lung cancer

    NEXT STORY
    Ophthalmic Diagnostic Devices Market to Reach USD 3.86 Billion by 2026; Increasing Prevalence of Ocular Disorders to Boost Growth: Fortune Business Insights™
    PREV STORY
    Teleflex to Present at the Raymond James 41st Annual Institutional Investors Conference
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Summit Therapeutics to Present at the Biotech Showcase

    OXFORD, United Kingdom, Jan. 09, 2018 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), ...

    author_avatar
    NASDAQ Market News

    GENFIT Launches The NASH Education Program to Increase Disease Awareness around NASH

    GENFIT Launches The NASH Education ProgramTM to Increase Disease Awareness around NASH Endowment fund ...

    author_avatar
    NASDAQ Market News

    Mundipharma brings its cancer supportive care expertise to Vietnam after signing agreement with Helsinn Group for ALOXI® (palonosetron HCl) 

    Mundipharma brings its cancer supportive care expertise to Vietnam after signing agreement with Helsinn ...

    author_avatar
    NASDAQ Market News